| Literature DB >> 29844412 |
Alexandra Sorvina1, Christie A Bader1, Jack R T Darby2, Mitchell C Lock2, Jia Yin Soo2, Ian R D Johnson1, Chiara Caporale3, Nicolas H Voelcker4,5, Stefano Stagni6, Massimiliano Massi1,3, Janna L Morrison2, Sally E Plush7,8, Douglas A Brooks9.
Abstract
Mitochondrial morphology is important for the function of this critical organelle and, accordingly, altered mitochondrial structure is exhibited in many pathologies. Imaging of mitochondria can therefore provide important information about disease presence and progression. However, mitochondrial imaging is currently limited by the availability of agents that have the capacity to image mitochondrial morphology in both live and fixed samples. This can be particularly problematic in clinical studies or large, multi-centre cohort studies, where tissue archiving by fixation is often more practical. We previously reported the synthesis of an iridium coordination complex [Ir(ppy)2(MeTzPyPhCN)]+; where ppy is a cyclometalated 2-phenylpyridine and TzPyPhCN is the 5-(5-(4-cyanophen-1-yl)pyrid-2-yl)tetrazolate ligand; and showed that this complex (herein referred to as IraZolve-Mito) has a high specificity for mitochondria in live cells. Here we demonstrate that IraZolve-Mito can also effectively stain mitochondria in both live and fixed tissue samples. The staining protocol proposed is versatile, providing a universal procedure for cell biologists and pathologists to visualise mitochondria.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29844412 PMCID: PMC5974328 DOI: 10.1038/s41598-018-24672-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1IraZolve-Mito detects mitochondria in live cardiac and skeletal muscle samples. Representative confocal micrographs showing mitochondria detected with IraZolve-Mito in cardiac (a; enlarged in a) and skeletal (c; enlarged in c) muscle samples. Endogenous NAD(P)H detected by two-photon microscopy in cardiac (b; enlarged in b) and skeletal (d; enlarged in d) muscle samples (excited at 740 nm and collected at 474–504 nm). Micrographs showing co-staining of mitochondria with IraZolve-Mito (green in e–e and f–f) and MitoTracker Red CMXRos (red in e,e,e and f,f,f) in cardiac (e; enlarged in e–e) and skeletal (f; enlarged in f–f) muscle samples. Scale bars: 20 µm (a–f) and 5 µm (a–d, e–e and f–f).
Figure 2Staining pattern of IraZolve-Mito is maintained in fixed cardiac and skeletal muscle samples. Representative confocal micrographs showing subcellular distribution of IraZolve-Mito in 4% PFA fixed cardiac (a; enlarged in a) and skeletal (c; enlarged in c) muscle samples. Confocal micrographs showing localisation of Cytochrome C detected with anti-Cytochrome C antibody in cardiac (b enlarged in b) and skeletal (d; enlarged in d) muscle samples. Micrographs showing co-staining of mitochondria with IraZolve-Mito (green in e–e and f–f) and MitoTracker Red CMXRos (red in e,e,e and f,f,f) in cardiac (e; enlarged in e–e) and skeletal (f; enlarged in f–f) muscle samples. Scale bars: 20 µm (a–f) and 5 µm (a–d, e–e and f–f).
Figure 3Inhibition of mitochondrial membrane potential in H9c2 rat cardiomyoblasts does not disrupt IraZolve-Mito staining. (a–a) Micrographs showing co-staining of IraZolve-Mito (green in a; greyscale in a) with MitoTracker Red CMXRos (red in a; greyscale in a) in cardiomyoblasts. Scale bars: 20 µm. Cardiomyoblasts were stained with IraZolve-Mito (b,c), MitoTracker Red CMXRos (d,e) or by anti-Cytochrome C antibody (f,g) either under normal conditions (control; b,d,f) or following treatment with FCCP (c,e,g). Scale bars: 20 µm.